Lumida
/HCA
⌘K
HCA Healthcare Inc

HCA Healthcare Inc

HCA
$426.94USD+1.36%+5.73 today

MARKET CAP

92.4B

P/E (TTM)

14.7x

FWD P/E

DAY RANGE

$421 – $429

52W RANGE

$354
$557

AI Summary

Stalk
Buy NowMedium

HCA has formed a series of higher highs and higher lows since bottoming in mid-June and is holding above the rising 9-/20-day EMAs and 50-day SMA. Medium-term structure remains bullish within Stage 2, though the 200-day SMA overhead is a key hurdle. Short-term conditions favor participation now on shallow pullbacks into the EMAs, while a drop below the 50-day SMA would invalidate the current bullish bias.

  • Q2 2026 revenue of $20.23B (+8.7% YoY) with diluted EPS of $7.62
  • 19th consecutive quarter of volume growth supports demand resilience
  • Insured-patient mix down 15%, reducing adjusted EBITDA by ~$400M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$58.8B$60.2B$65.0B$70.6B$75.6B
YoY %+14.0%+2.5%+7.9%+8.7%+7.1%
P / Sales1.4x1.2x1.2x1.1x1.5x
EV / Sales2.3x2.0x2.0x1.9x2.3x
Gross Profit, Adj.$58.8B$60.2B$65.0B$70.6B$75.6B
YoY %+14.0%+2.5%+7.9%+8.7%+7.1%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit2.3x2.0x2.0x1.9x2.3x
EBITDA, Adj.$12.5B$12.0B$12.7B$13.9B$15.5B
YoY %+25.5%-4.1%+5.6%+9.2%+11.9%
Margin %21.3%20.0%19.5%19.6%20.5%
EV / EBITDA10.6x10.3x10.3x9.8x11.2x
EBIT$9.7B$9.1B$9.6B$10.6B$12.0B
YoY %+33.3%-6.5%+6.3%+9.8%+13.6%
Margin %16.5%15.0%14.8%15.0%15.9%
EV / EBIT13.7x13.6x13.5x12.8x14.5x
Net Income$7.0B$5.6B$5.2B$5.8B$6.8B
YoY %+85.3%-18.9%-7.1%+9.9%+17.8%
Net Margin11.8%9.4%8.1%8.2%9.0%
EPS (GAAP)$21.16$19.15$18.97$22.00$28.33
YoY %+93.6%-9.5%-0.9%+16.0%+28.8%